Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845042 | 0.77 | ATM (0.32) | FGFR1KDR | |
| SCHEMBL21903125 | 0.77 | HDAC8 (0.32) | FGFR1 | |
| SCHEMBL5495169 | 0.77 | SMPD3 (0.37) | FGFR1 | |
| SCHEMBL9609557 | 0.72 | GRIA1 (0.32) | — | |
| SCHEMBL6842141 | 0.72 | ALOX15 (0.32) | — | |
| SCHEMBL15598312 | 0.72 | RAB9A (0.33) | — | |
| SCHEMBL25414914 | 0.71 | KDR (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16146595 | 0.71 | KDM4C (0.42) | — | |
| SCHEMBL20029255 | 0.70 | CCNK (0.38) | FLT1FLT4KDR | |
| SCHEMBL73454 | 0.70 | AXL (0.47) | AXLFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322199-B | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118684667-A | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-12060355-B2 | Compounds for use in the treatment of fascioliasis | MERCK PATENT GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| CN-112512636-B | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-3801499-B1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-20220194933-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-06-23 | — | — | US | disclosed |
| EP-3568397-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS | MERCK PATENT GMBH (DE) | 2022-04-13 | — | — | EP | disclosed |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1797096-A2 | NOVEL PYRAZOLOPYRIMIDINES | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027346-A2 | NOVEL PYRAZOLOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | AXL 4698/4885PRKAB2 620/4885PRKAG1 373/4885 |
| US-12060355-B2 | Compounds for use in the treatment of fascioliasis | SLC10A1, SLC10A2, MGST3 | AXL 2315/4885PRKAB2 3913/4885PRKAG1 4025/4885 |
| US-20220194933-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, SARNP | AXL 4604/4885PRKAB2 750/4885PRKAG1 381/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | AXL 4700/4885PRKAB2 973/4885PRKAG1 641/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | AXL 2601/4885PRKAB2 1849/4885PRKAG1 1520/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | AXL 1505/4885PRKAB2 704/4885PRKAG1 533/4885 |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | AXL 3965/4885PRKAB2 1186/4885PRKAG1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.